一个致命的美国流感季节未能提高疫苗率,由于长期犹豫不决而损害了CSL的库存和疫苗单位计划。 A deadly U.S. flu season failed to boost vaccine rates, hurting CSL’s stock and vaccine unit plans due to lasting hesitancy.

2024-2025年的美国严重流感季节与多达99,000人死亡有关,未能刺激流感疫苗需求,因为疫苗接种率又下降了14%至15%,并持续多年下降。 A severe 2024–2025 U.S. flu season, linked to up to 99,000 deaths, failed to boost flu vaccine demand as vaccination rates dropped another 14% to 15%, continuing a multi-year decline. 分析家将这一趋势归因于持续的疫苗犹豫不决和公共卫生信息被削弱,特别是在反疫苗活动家Robert F. Kennedy Jr. 成为特朗普政府卫生秘书之后。 Analysts attribute the trend to persistent vaccine hesitancy and weakened public health messaging, particularly after anti-vaccine activist Robert F. Kennedy Jr. became health secretary under the Trump administration. 这次跌幅严重影响了澳大利亚制药公司CSL,该公司在美国拥有最大的市场,造成超过500亿美元的市值损失,17亿美元的减值,以及无限期推迟分拆其疫苗部门Seqirus. The drop severely impacted CSL, an Australian drugmaker with its largest market in the U.S., causing over $50 billion in lost market value, a $17 billion write-down, and the indefinite postponement of spinning off its vaccine unit, Seqirus. 该公司指出,尽管发生了危机,公众仍会遇到意外抵制,这反映出在维持对疫苗的信任方面存在更广泛的挑战。 The company cited unanticipated public resistance despite the crisis, reflecting broader challenges in maintaining trust in vaccines.